--- title: "Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside" type: "News" locale: "en" url: "https://longbridge.com/en/news/296831532.md" description: "Ascendis Pharma reported Q2 2026 sales of €339.29 million and net income of €206.97 million, marking a shift from last year's loss. Despite recent positive share price momentum, the stock is considered undervalued with a fair value of $313.36 versus its current $253.29 price. This valuation relies on TransCon product portfolio growth, particularly YORVIPATH adoption. Key risks include potential uptake slowdowns or approval delays for other products." datetime: "2026-08-24T21:32:27.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296831532.md) - [en](https://longbridge.com/en/news/296831532.md) - [zh-HK](https://longbridge.com/zh-HK/news/296831532.md) generator: "portal-rs" --- # Ascendis Pharma (ASND) On Profitability, The Valuation Narrative Still Points To Upside ## Ascendis Pharma earnings event and why it matters for shareholders Ascendis Pharma (NasdaqGS:ASND) recently reported second quarter 2026 results, with sales of €339.29 million and net income of €206.97 million, following a net loss in the same period a year earlier. See our latest analysis for Ascendis Pharma. Following the strong second quarter earnings shift into profitability, Ascendis Pharma's 7 day share price return of 2.38% and 90 day share price return of 5.69% suggest momentum has picked up. However, the year to date share price return of 3.22% points to a more measured longer term move around the current $253.29 level. If Ascendis Pharma's recent results have caught your attention, it can help to compare it with other potential growth stories in healthcare. Take the next step and review 41 healthcare AI stocks. After Ascendis Pharma's sharp swing into profit and a more modest share price move, the real test now is whether the current valuation still leaves more upside than downside risk for new buyers. ## Most Popular Narrative: 19.2% Undervalued At a last close of $253.29 versus a narrative fair value of $313.36, Ascendis Pharma is framed as materially undervalued, with that view anchored in the TransCon product portfolio. > *Broader adoption of YORVIPATH in chronic hypoparathyroidism, with only a small share of eligible U.S. patients currently on therapy and access expanding across more than 30 countries, can widen the treated patient base and support recurring product revenue and operating cash flow.* Read the complete narrative. Want to see what is assumed behind that upside gap? The narrative leans heavily on rapid revenue expansion, high margins and a premium earnings multiple that lifts the fair value above the current share price. **Result: Fair Value of $313.36 (UNDERVALUED)** Have a read of the narrative in full and understand what's behind the forecasts. However, there are still clear risks to the Ascendis Pharma story, especially if YORVIPATH uptake slows or if TransCon CNP and Yuviwel approvals and rollouts face delays. Find out about the key risks to this Ascendis Pharma narrative. ## Next Steps With Ascendis Pharma showing both clear upside drivers and real risk flags, it makes sense to move fast and review the full picture for yourself. A useful place to start is by weighing up the 4 key rewards and 1 important warning sign. ## Looking for more investment ideas beyond Ascendis Pharma? If Ascendis Pharma has sharpened your focus, do not stop here. Use the Simply Wall St screener to uncover other opportunities that could fit your portfolio. - Target steadier potential returns by scanning companies with strong income profiles through the 12 dividend fortresses. - Hunt for opportunities where price and fundamentals may be out of sync by checking the 48 high quality undervalued stocks. - Prioritise capital preservation by focusing on companies assessed with lower overall risk in the 75 resilient stocks with low risk scores. *This article by Simply Wall St is general in nature. **We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.** It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.* ### **New:** Manage All Your Stock Portfolios in One Place We've created the **ultimate portfolio companion** for stock investors, **and it's free.** • Connect an unlimited number of Portfolios and see your total in one currency • Be alerted to new Warning Signs or Risks via email or mobile • Track the Fair Value of your stocks Try a Demo Portfolio for Free ### Related Stocks - [ASND.US](https://longbridge.com/en/quote/ASND.US.md) ## Related News & Research - [If You Invested $1000 In Ascendis Pharma Stock 10 Years Ago, You Would Have This Much Today](https://longbridge.com/en/news/297063733.md) - [Ascendis Announces Oral Presentation of Week 104 Data from Its Pivotal Trial of TransCon® CNP (Navepegritide) at ISDS 2026 | ASND Stock News](https://longbridge.com/en/news/296951291.md) - [Ascendis Pharma A/S (NASDAQ:ASND) Director Jean Jacques Bienaime Purchases 2,000 Shares of Stock](https://longbridge.com/en/news/296295409.md) - [Ascendis Pharma Files Strong Interim Q2 2026 Results on Form 6-K](https://longbridge.com/en/news/295797900.md) - [Ascendis Pharma director Jean-Jacques Bienaime buys USD 492,079 of common shares](https://longbridge.com/en/news/296284390.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**